Muhammad Maaz Amjad

Muhammad Maaz Amjad

Auto-generated profile, based on publicly available information

Muhammad Maaz Amjad

Khyber Medical College, Peshawar, Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2025 in Brain Research
Verified
Journal Article
Closed access
MAMuhammad Maaz Amjad
Muhammad Maaz Amjad
HJHadiya Javed
Hadiya Javed
MAMuhammad Zuhaz Azeem
Muhammad Zuhaz Azeem
TATuyyab Anwer
Tuyyab Anwer
BKBilal Wazir Khan
Bilal Wazir Khan
KKKomal Khan
Komal Khan

22 September 2026 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
MKMuhammad Huzaifa Khattak
Muhammad Huzaifa Khattak
SASyed Aqeel Abbas
Syed Aqeel Abbas
UZUmer Zaryab
Umer Zaryab
HBHumaira Bibi
Humaira Bibi
SSShahreena Athar Siddiqui
Shahreena Athar Siddiqui
HKHaris Wazir Khan
Haris Wazir Khan

29 September 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
MAMuhammad Maaz Amjad
Muhammad Maaz Amjad
MKMuhammad Mustafa Khan
Muhammad Mustafa Khan
FSFatima Sarwar
Fatima Sarwar
AAAqsa Ali
Aqsa Ali
MAMaham Ali
Maham Ali
BKBilal Wazir Khan
Bilal Wazir Khan

17 August 2026 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
MAMuhammad Maaz Amjad
Muhammad Maaz Amjad
MBMuaz Shehzar Bashir
Muaz Shehzar Bashir
KMKhwaja Waleed Maqbool
Khwaja Waleed Maqbool
TQTayyaba Ikram Qazi
Tayyaba Ikram Qazi
MAMinahil Ali
Minahil Ali
BKBilal Wazir Khan
Bilal Wazir Khan
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options. Platinum agents, particularly carboplatin's DNA damaging properties suggest efficacy, its impact on survival outcomes and toxicity remains uncertain. Methods: PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched from inception to February 2026. Phase II/III RCTs comparing carboplatin plus standard chemotherapy with standard therapy alone in TNBC were included. Primary outcomes were disease-free survival (DFS), overall survival (OS), and pathological complete response (pCR). Pooled hazard ratios (HRs) and risk ratios (RRs) were calculated using random-effects models. Results: Twenty-three trials (n = 8797) were included. Carboplatin significantly improved DFS (HR 0.68, 95% CI 0.60–0.76), OS (HR 0.65, 95% CI 0.53–0.80), and pCR (RR 1.46, 95% CI 1.30–1.64). Improvements were also observed in distant disease-free survival and recurrence-free survival. However, carboplatin was associated with increased hematological toxicities, including anemia, neutropenia, and thrombocytopenia, and higher rates of dose reduction and treatment discontinuation, though treatment-related mortality was not significant. Conclusion: Carboplatin-containing chemotherapy improves survival outcomes and pCR in TNBC. Despite increased toxicity, adverse effects are generally manageable. These findings support the incorporation of carboplatin into TNBC treatment, with careful patient selection to balance efficacy and safety.

18 September 2026 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
MAMuhammad M. Amjad
Muhammad M. Amjad
MRMaryam Rafique
Maryam Rafique
SHSyeda F. Hussain
Syeda F. Hussain
MMMehroz Mustafa
Mehroz Mustafa
TQTayyaba I. Qazi
Tayyaba I. Qazi
BKBilal W. Khan
Bilal W. Khan
Objectives: Sacituzumab govitecan (SG), a Trop-2–directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to evaluate the effectiveness and safety of SG using only randomized controlled trials (RCTs). Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed/MEDLINE, Embase, Scopus, and Cochrane Library were searched from June 2025 to April 2026. RCTs comparing SG with standard therapies in breast cancer patients were included. Outcomes included objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and grade ≥3 adverse events. Random-effects models were used to calculate pooled risk ratios (RR) and hazard ratios (HR) with 95% CIs. Risk of bias (RoB 2) and GRADE approaches were applied. Results: Six RCTs (n=2508) were included. SG significantly improved ORR (RR=1.62; 95% CI: 1.11-2.37), OS (HR=0.68; 95% CI: 0.54-0.86), and PFS (HR=0.60; 95% CI: 0.51-0.72), although heterogeneity was moderate to high in some analyses. SG was associated with a higher risk of grade ≥3 adverse events (RR=1.12; 95% CI: 1.05-1.20), particularly diarrhea and neutropenia. Subgroup and sensitivity analyses confirmed the robustness of efficacy outcomes. Conclusions: SG provides significant improvements in survival and response outcomes in advanced breast cancer, with a manageable toxicity profile. These findings support its role as an effective treatment option, particularly in pretreated patients, while highlighting the need for further research to optimize its clinical use.